SynthesisJournal of cancer research and clinical oncology2014
Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis.
Synthesis in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Serum vitamin D levels and prostate cancer: an umbrella review and pooled analysis of observational meta-analyses.Frontiers in oncology · 2026Pooled it
- Research on potential biomarkers of prostate cancer in Latin America and the Caribbean: a scoping review.Frontiers in oncology · 2026Pooled it
- Pooled it
- Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses.PLoS medicine · 2024Pooled it
- Vitamin D and Multiple Health Outcomes: An Umbrella Review of Observational Studies, Randomized Controlled Trials, and Mendelian Randomization Studies.Advances in nutrition (Bethesda, Md.) · 2022Pooled it
- Circulating 25-Hydroxyvitamin D and Prostate Cancer Survival.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Trial
- Article
- Serum 25-hydroxyvitamin D levels and risk of overall and site-specific cancers in Korean adults: results from two prospective cohort studies.Nutrition journal · 2025Article
- Vitamin D-related genetic variants and prostate cancer risk in Black men.Cancer epidemiology · 2025Article
- The double disparity: Vitamin D deficiency and lethal prostate cancer in black men.The Journal of steroid biochemistry and molecular biology · 2025Review
- Key genes of vitamin D metabolism and their roles in the risk and prognosis of cancer.Frontiers in genetics · 2025Review
- Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer.International journal of molecular sciences · 2024Review
- Causal association between 25-hydroxyvitamin D status and cataract development: A two-sample Mendelian randomization study.World journal of clinical cases · 2024Article
- Discordant Health Implications and Molecular Mechanisms of Vitamin D in Clinical and Preclinical Studies of Prostate Cancer: A Critical Appraisal of the Literature Data.International journal of molecular sciences · 2024Review
- Serum Level of Vitamin D in Patients with Salivary Gland Tumors.Iranian journal of otorhinolaryngology · 2023Article
- Vitamin D, a Regulator of Androgen Levels, Is Not Correlated to PSA Serum Levels in a Cohort of the Middle Italy Region Participating to a Prostate Cancer Screening Campaign.Journal of clinical medicine · 2023Article
- The Four Horsemen of the Apocalypse: Cancer, Depression, Vitamin D Deficiency, and Obesity: An Observational Study.Disease markers · 2023Observational
- How competing risks affect the epidemiological relationship between vitamin D and prostate cancer incidence? A population-based study.Andrologia · 2022Article
- Vitamin D deficiency: a potential risk factor for cancer in obesity?International journal of obesity (2005) · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate and clarify the relationship between circulating 25-hydroxyvitamin D level and prostate cancer risk.
methodsWe conducted the meta-analysis to better evaluate the association. Terms "25-Hydroxyvitamin D"/"vitamin D" and "prostate cancer" were used for literature search.
resultsWe identified 21 relevant publications from databases of PubMed and MEDLINE and included 11,941 cases and 13,870 controls in the meta-analysis. Overall studies revealed a significant 17 % elevated risk of prostate cancer for individuals with higher level of 25-hydroxyvitamin D (OR = 1.17, 95 % CI = 1.05-1.30, P = 0.004), and no publication bias was found in the calculations (P = 0.629). Subgroup analysis confirmed the association from nested case-control study group, studies from USA group and studies using serum samples group (nested case-control studies: OR = 1.17, 95 % CI = 1.08-1.27, P < 0.001; USA: OR = 1.15, 95 % CI = 1.03-1.29, P = 0.017; serum: OR = 1.20, 95 % CI = 1.01-1.42, P = 0.042); moreover, sensitivity tests also indicated significant results in studies from Europe and studies conducting with plasma samples after exclusion of some influential single study from the analysis, respectively (Europe: OR = 1.21, 95 % CI = 1.04-1.40, P = 0.014; plasma: OR = 1.13, 95 % CI = 1.00-1.27, P = 0.05).
conclusionsOur meta-analysis, for the first time, suggested significant positive relationship between high level of 25-hydroxyvitamin D and increased risk of prostate cancer, reminding us that more concern should be taken into account during assessing the effect of 25-hydroxyvitamin D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.